Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors

Oncogene

Volumn 23, Issue 22, 2004, Pages 3972-3979

  Schreiber, Karin ^a   Cannon, Ronald E ^b   Karrison, Theodore ^a   Beck Engeser, Gabriele ^a   Huo, Dezheng ^a   Tennant, Raymond W ^b   Jensen, Heather ^a   Kast, W Martin ^c   Krausz, Thomas ^a   Meredith, Stephen C ^a   Chen, Lieping ^d   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

E6 E7; HPV 16; Human papilloma virus 16; Primary tumors; Synergy; Transgenic mice; vHa ras

Indexed keywords

PROTEIN E6; PROTEIN E7; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; RAS PROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EAR TUMOR; EYE TUMOR; GENE MUTATION; MOUSE; MOUTH TUMOR; NONHUMAN; ONCOGENE RAS; PREVALENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR; TUMOR GROWTH; VIRUS GENE; WART VIRUS; ANIMAL; C57BL MOUSE; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; NEOPLASM;

ANIMALIA; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MUS MUSCULUS; PAPILLOMAVIRUS; PAPOVAVIRIDAE;

ANIMALS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; RAS PROTEINS; REPRESSOR PROTEINS;

EID: 2542583106     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207507     Document Type: Article

References (58)

1. Alonio LV, Dalbert D, Picconi MA, Cervantes Vazquez G, Garcia Carranca A, Distefano AL, Mural J, Bartt O, Bazan G and Teyssie AR. (2000). Medicina, 60, 895-901.
2. Alonio LV, Picconi MA, Dalbert D, Mural J, Bartt O, Bazan G, Dominguez M and Teyssie AR. (2003). J. Clin. Virol., 27, 263-269.
3. Arbeit JM, Munger K, Howley PM and Hanahan D. (1994). J. Virol., 68, 4358-4368.
4. Bailleul B, Surani MA, White S, Barton SC, Brown K, Blessing M, Jorcano J and Balmain A. (1990). Cell, 62, 697-708.
5. Balkwill F and Mantovani A. (2001). Lancet, 357, 539-545.
6. Bergmann K, Hoppe F, He Y, Helms J, Muller-Hermelink HK, Stremlau A and de Villiers EM. (1994). Int. J. Cancer, 59, 463-466.
7. Breslow N. (1970). Biometrika, 57, 579.
8. Campo MS. (1998). Trends Microbiol., 6, 424-426.
9. Coussens LM, Hanahan D and Arbeit JM. (1996). Am. J. Pathol., 149, 1899-1917.
10. Coussens LM, Tinkle CL, Hanahan D and Werb Z. (2000). Cell, 103, 481-490.
11. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid III PG, Durst M, Gissmann L, Roman A and Turek LP. (1987). EMBO J., 6, 3745-3753.
12. Crook T, Storey A, Almond N, Osborn K and Crawford L. (1988). Proc. Natl. Acad. Sci. USA, 85, 8820-8824.
13. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM and Hanahan D. (2003). J. Exp. Med., 197, 1017-1028.
14. Dokianakis DN, Papaefthimiou M, Tsiveleka A and Spandidos DA. (1999). Oncol. Rep., 6, 1327-1331.
15. Drinkwater NR and Bennett LM. (1991). Prog. Exp. Tumor Res., 33, 1-20.
16. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith L and Kast WM. (2002). Cancer Res., 62, 5792-5799.
17. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ and Kast WM. (1993). Eur. J. Immunol., 23, 2242-2249.
18. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ and Kast WM. (1995). Eur. J. Immunol., 25, 2638-2642.
19. Gillison EW, Powell DJ, McConkey C and Spychal RT. (2000). Br. J. Surg., 87, 362-373.
20. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE and Hayday AC. (2001). Science, 294, 605-609.
21. Gloss B, Bernard HU, Seedorf K and Klock G. (1987). EMBO J., 6, 3735-3743.
22. Golijow CD, Mouron SA, Gomez MA and Dulout FN. (1999). Gynecol. Oncol., 75, 108-112.
23. Greenhalgh DA, Wang XJ, Rothnagel JA, Eckhardt JN, Quintanilla MI, Barber JL, Bundman DS, Longley MA, Schlegel R and Roop DR. (1994). Cell Growth Differ., 5, 667-675.
24. Hansen LA and Tennant R. (1994). Mol. Carcinog., 9, 143-154.
25. IARC (International Agency for Research on Cancer) (1995a). Monographs on the evaluation of carcinogenic risks to humans. Human papilloma virus. Vol 64, p. 65.
26. IARC. (International Agency for Research on Cancer) (1995b). Monographs on the evaluation of carcinogenic risks to humans. Human papilloma virus. Vol 64, p. 245.
27. Janicek MF and Averette HE. (2001). CA Cancer J. Clin., 51, 92-114.
28. Jin YT, Tsai ST, Li C, Chang KC, Yan JJ, Chao WY, Eng HL, Chou TY, Wu TC and Su IJ. (1997). Am. J. Pathol., 150, 1327-1333.
29. Kantz DC, Lacks GD and Cannon RE. (1999). Biotechniques, 27, 278-280.
30. Kaplan E and Meier P. (1958). J. Am. Stat. Assoc., 53, 457-481.
31. Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, Caceres E, Peixoto-Guimaraes D, Lenoir G, Hainaut P, Walboomers JM and Munoz N. (2001). Cancer Epidemiol. Biomarkers Prev., 10, 1009-1012.
32. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ and Fuchs PG. (2001). Cancer, 92, 2875-2884.
33. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M and Griep AE. (1993). Proc. Natl. Acad. Sci. USA, 90, 5583-5587.
34. Leder A, Kuo A, Cardiff RD, Sinn E and Leder P. (1990). Proc. Natl. Acad. Sci. USA, 87, 9178-9182.
35. Lee JH, Lee SK, Yang MH, Ahmed MM, Mohiuddin M and Lee EY. (1996). Gynecol. Oncol., 62, 49-54.
36. Lin XH, Dahlin-Huppe K and Stallcup WB. (1996). J. Cell. Biochem., 63, 463-477.
37. Mazurek S, Zwerschke W, Jansen-Durr P and Eigenbrodt E. (2001). Oncogene, 20, 6891-6898.
38. Melero I, Singhal MC, McGowan P, Haugen HS, Blake J, Hellstrom KE, Yang G, Clegg CH and Chen L. (1997). J. Virol., 71, 3998-4004.
39. Mouron SA, Abba MC, Guerci A, Gomez MA, Dulout FN and Golijow CD. (2000). Mutat. Res., 469, 127-134.
40. Pedroza-Saavedra A, Cruz A, Esquivel F, De La Torre F, Berumen J, Gariglio P and Gutierrez L. (2000). Arch. Virol., 145, 603-623.
41. Phelps WC, Yee CL, Munger K and Howley PM. (1988). Cell, 53, 539-547.
42. Prokopakis P, Sourvinos G, Koumantaki Y, Koumantakis E and Spandidos DA. (2002). Oncol. Rep., 9, 129-133.
43. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ and Kast WM. (1995). J. Immunol., 154, 5934-5943.
44. Riley RR, Duensing S, Brake T, Munger K, Lambert PF and Arbeit JM. (2003). Cancer Res., 63, 4862-4871.
45. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M and Kelsey KT. (2002). Clin. Cancer Res., 8, 3187-3192.
46. Riou G, Barrois M, Sheng ZM, Duvillard P and Lhomme C. (1988). Oncogene, 3, 329-333.
47. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH and Spiegelman BM. (1995). Cell, 82, 721-732.
48. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL and Franco EL. (2003). J. Natl. Cancer Inst., 95, 1336-1343.
49. Scott IU, Karp CL and Nuovo GJ. (2002). Ophthalmology, 109, 542-547.
50. Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu Y, Rowley DA and Schreiber H. (2000). J. Exp. Med., 191, 1945-1956.
51. Song S, Pitot HC and Lambert PF. (1999). J. Virol., 73, 5887-5893.
52. Stenzel A, Semczuk A, Rozynskal K, Jakowicki J and Wojcierowski J. (2001). Pathol. Res. Pract., 197, 597-603.
53. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and Banks L. (1998). Nature, 393, 229-234.
54. Thompson KL, Rosenzweig BA and Sistare FD. (1998). Toxicol. Pathol., 26, 548-555.
55. Tsai ST, Li C, Jin YT, Chao WY and Su IJ. (1997). Int. J. Cancer, 71, 208-212.
56. Willis G, Jennings B, Ball RY, New NE and Gibson I. (1993). Gynecol. Oncol., 49, 359-364.
57. zur Hausen H. (2000). J. Natl. Cancer Inst., 92, 690-698.
58. zur Hausen H. (2002). Nat. Rev. Cancer, 2, 342-350.